Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
Recruiting · NCT07241793 · Registry updated 2026-04-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) | Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma, urothelial carcinoma | Recruiting | Phase 2 | 2026-04-30 | NCT07241793 |
5 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Jiangxi Cancer Center | Nanchang | China | 1 |
| Sun Yat-sen Memorial Hospital of Sun Yat-sen University | Guangzhou | China | 12 |
| Sun Yat-sen University Cancer Center | Guangzhou | China | 61 |
| The fifth Affiliated Hospital of Guangzhou Medcial University | Guangzhou | China | 1 |
| The Second Affiliated Hospital of Kunming Medical University | Kunming | China | 2 |
| Tongji Hospital, Affiliated to Tongji Medical College of Huazhong University of Science and Technology | Wuhan | China | 1 |